信大医学部医学科研究紹介2020(英語版)
28/48

26From high quality surgery to gene therapy- New challenge to cancer treatment -Digestive tract surgeryDigestive tract surgery((Chief: Assistant Prof. Yusuke MiyagawaChief: Assistant Prof. Yusuke Miyagawa))Surgery(Gastroenterological)Summary of ActivityThe basis of treatment for esophageal, gastric and colorectal cancer is surgical resection, and we are working on improving quality surgery further pursuing mini-mally invasive, radical and safety.We are also focusing on basic research directly linked to clinical practice. Using the flow cytometer and the latest cell imaging equipment Operetta, we aimed to develop new treatments targeting RAS and BRAF gene mutations of colorectal cancer and RhoA gene mutations of scirrhous gastric cancer.・Establishment of in vitro assay corresponding to individualized treatment of colorectal and gastric cancer・Functional analysis of mutant RHOA in scirrhous gastric cancer・Intraoperative monitoring of recurrent nerve injury of esophageal surgerySince our research method uses a flow cytometer and a cell imaging device (Operetta), functional analysis of many genetic mutations and drug resistance can be efficiently evaluat-ed.Because you can learn a wide range of basic knowledge of cancer and research method us-ing the latest equipment, in the case of getting involved in cancer research and clinical work, the knowledge and technology obtained in this study seems very useful.Research subjectOutlook for researchOutlook for students after graduationGene mutation increases the malignancy of cancer, but at the same time it may be-come a therapeutic targetUsing a ow cytometer (BD FACS Cant II), it is possible to obtain more objective and stable resultsExploring perioperative and long-term problems associated with liver transplantation Promoting pancreatic islet cell transplantationTransplant and Pediatric SurgeryTransplant and Pediatric Surgery((Chief: Senior Assistant Prof. Atsuyoshi MitaChief: Senior Assistant Prof. Atsuyoshi Mita))Surgery(Gastroenterological)Summary of Activity・The first case of living donor liver transplantation in our institute was per-formed in 1990, and more than 300 cases have been experienced. We will continue to provide careful patient care to overcome life threatening problems, such as rejection, infection, and de novo cancer after transplantation. ・For clinical islet transplantation program, our institution is approved by Minister for HLW* to provide Class I Regenerative Medicine under the Act on the Safe-ty of Regenerative Medicine in 2015.・To solve perioperative and long-term problems associated with liver transplantation・Simulation training to improve islet isolation techniques ・To investigate how to protect pancreatic islets・Appling knowledge of our over 20 years of practice to improve the outcome after liver transplantation・To promote islet transplantation therapy in Japan along with other institutions・To become a transplant surgeon having a deep knowledge of immune system, cell protec-tion, and patient care.Research subjectOutlook for researchOutlook for students after graduationThe upper graph is Kaplan-Meier patient survival curve. The over all survival in a total of 39 cases for recent seven years was 95%. Islets for islet transplantationIslets (stained on red) isolated from a donor’s pancreas are transplanted into the liver through the portal vein.Gene mutated cancer cells are mea-sured with a ow cytometer* Health, Labour and WelfareRAS-mutated cells

元のページ  ../index.html#28

このブックを見る